Core Insights - The article highlights the advancements in proton therapy technology by China General Nuclear Power Group (CGN) and its subsidiary, CGN Medical Technology, which has established the first commercial multi-room proton therapy system production base in China [1] - The 230 MeV cyclotron, a key component of the proton therapy system, has been successfully produced, with three units completed in the first year of operation [1] - The company aims to achieve a world-class nuclear medical industry by 2030, leveraging local research and manufacturing capabilities in Mianyang, Sichuan [1] Company Overview - CGN Medical Technology has adopted a strategy of "introduction, digestion, absorption, and re-innovation" to develop its proton therapy systems, following successful practices in China's nuclear power sector [1] - The proton therapy system consists of 227 main devices and approximately 155,000 components, showcasing its complexity and technological sophistication [1] - The company has formed partnerships with over 80 upstream and downstream enterprises in the industry, promoting continuous technological innovation [1] Industry Context - The Sichuan province has implemented supportive policies to foster the development of the nuclear medical industry, aiming to establish itself as a global leader in medical isotope production and nuclear medical equipment manufacturing by 2030 [1] - The region's strong research and manufacturing foundation, exemplified by institutions like the China Engineering Physics Research Institute, contributes to the rapid growth of the nuclear medical sector in Mianyang [1] - The article emphasizes the potential for China to export its advanced imaging and treatment technologies internationally, marking a significant step in the global nuclear medical landscape [1]